AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00446563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 100 mg tablets taken orally once daily in the morning.
Study NCT02213055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LICEMD
Description: Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
Study NCT02213055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Head lice product
Description: The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
Study NCT02361593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assistance of a transparent cap
Description: Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
Study NCT01223105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slow freeze
Description: Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
Study NCT01223105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrification
Description: Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
Study NCT04229121 — intervention group
Intervention type: OTHER
Intervention: nonintervention
Description: nonintervention
Study NCT04535076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation
Description: Transcatheter Aortic Valve Implantation
Study NCT04535076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Aortic Valve Replacement
Description: Surgical Aortic Valve Replacement
Study NCT01330576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cooling blanket/mattress
Description: Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
Study NCT01330576 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment of care at normothermia
Description: Standard treatment of care in 33.5C for 48 hours
Study NCT04187352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001+ Fluorouracil+Cisplatin
Description: CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.
Study NCT04187352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo+ Fluorouracil+Cisplatin
Description: Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.
Study NCT01488058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxIGen + iCBT
Description: OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
Study NCT01488058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Waitlist will receive iCBT at week 11
Study NCT04306133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.
Study NCT04306133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Infiltration
Description: At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
Study NCT04306133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Infiltration
Description: At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
Study NCT02494479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prurisol
Description: 50mg tablet
Study NCT02494479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill designed to match Purisol tablet
Study NCT03531021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart healthy intervention
Description: Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
Study NCT00667212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Twelve weekly therapy sessions, approximately one hour each in duration
Study NCT00667212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Twelve weekly therapy sessions, approximately one hour each in duration
Study NCT02902211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Description: Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
Study NCT02902211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control/standard of care
Description: Patients will carry out with typical activities suggested by their physician for three months.
Study NCT04222790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialic gangliosides
Description: The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
Study NCT02361593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without a transparent cap
Description: Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
Study NCT02323893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG
Study NCT02930564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDED + milk fat and gluten
Description: CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
Study NCT03702725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
Study NCT03702725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
Study NCT03702725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
Study NCT06190483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 5 Mg Oral Tablet
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
Study NCT06190483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 50 Mg Oral Tablet
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
Study NCT01725165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo clinical observation
Study NCT01725165 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT01725165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01725165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01725165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01725165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01725165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo standard maintenance therapy
Study NCT01725165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04122196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
Study NCT04122196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
Study NCT02406846 — intervention group
Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.
Study NCT02406846 — intervention group
Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study NCT02421198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YMCA Family Diabetes Prevention Program (YFDPP)
Description: 12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
Study NCT02113202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
Study NCT02113202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence endoscopy platform
Description: A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
Study NCT02054702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
Study NCT02054702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Up to 20 mg/day, once daily dose, tablets, orally
Study NCT02310594 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo blood sample collection
Study NCT02310594 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02337127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine, 100mg/day, per os
Study NCT04222790 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
Study NCT03196570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
Study NCT03196570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Contact Control
Description: Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
Study NCT04249830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
Study NCT04249830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS TCR α/β Reagent Kit and CliniMACS CD19
Description: The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
Study NCT01469650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferal
Description: 400 IU/day
Study NCT01469650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 800 IU/day D3
Study NCT00753389 — intervention group
Intervention type: OTHER
Intervention: None (anesthesia)
Description: anesthesia
Study NCT00440453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Nutritional therapy by dietician
Study NCT01364532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transulnar arterial access
Description: Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
Study NCT01364532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transradial arterial access
Description: Transradial arterial access for coronary angiography,ad-hoc or elective PCI
Study NCT02466503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhaled corticosteroid, pMDI
Study NCT02466503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Inhaled corticosteroid, pMDI
Study NCT02466503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol (as xinafoate)
Description: Beta-agonist, LABA, pMDI
Study NCT02466503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol (as xinafoate)
Description: Beta-agonist, LABA, pMDI
Study NCT02588287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws for tenofovir PK, renal function
Study NCT03081169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium 150 MG/ML Prefilled Syringe
Description: The same drugs and dosages will be used in both groups, with only the timing being different
Study NCT03081169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The same drugs and dosages will be used in both groups, with only the timing being different
Study NCT04828967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis is added to the conventional group
Study NCT01697046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada and Isentress
Description: Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days.
Study NCT01614223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACP
Description: Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
Study NCT01614223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid (celestone) injection
Description: Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
Study NCT03179267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNAP40
Description: SNAP40 ambulatory monitoring device
Study NCT03010501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Energy Density
Description: Food Energy density manipulated
Study NCT02430233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone 400 mg (Utrogestan)
Description: participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
Study NCT02272101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D versus placebo
Description: Cross-over design
Study NCT02272101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D versus placebo
Description: Cross-over design
Study NCT03796663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Parenting Program
Description: The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines.
Study NCT03796663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting Program
Description: The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines.